(Q33387009)

26 July 2017

title

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

1 reference

1 reference

1 reference

D A Reardon

1

1 reference

26 July 2017

G Dresemann

2

1 reference

26 July 2017

S Taillibert

3

1 reference

26 July 2017

M Campone

4

1 reference

26 July 2017

M van den Bent

5

1 reference

26 July 2017

P Clement

6

1 reference

26 July 2017

E Blomquist

7

1 reference

26 July 2017

L Gordower

8

1 reference

26 July 2017

H Schultz

9

1 reference

26 July 2017

J Raizer

10

1 reference

26 July 2017

P Hau

11

1 reference

26 July 2017

J Easaw

12

1 reference

26 July 2017

M Gil

13

1 reference

26 July 2017

J Tonn

14

1 reference

26 July 2017

A Gijtenbeek

15

1 reference

26 July 2017

U Schlegel

16

1 reference

26 July 2017

P Bergstrom

17

1 reference

26 July 2017

S Green

18

1 reference

26 July 2017

A Weir

19

1 reference

26 July 2017

Z Nikolova

20

1 reference

26 July 2017

language of work or name

English

0 references

publication date

10 November 2009

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

101

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

1995-2004

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Imatinib sensitizes CLL lymphocytes to chlorambucil

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

STI-571 inhibits in vitro angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Prevalence of KIT expression in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605411

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795431

31 October 2018

Identifiers

DOI

10.1038/SJ.BJC.6605411

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference